Genetics of Parkinson's disease and biochemical studies of implicated gene products

Current Opinion in Genetics and Development

Volumn 12, Issue 3, 2002, Pages 299-306

  Lansbury Jr, Peter T ^a   Brice, Alexis ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DJ 1 PROTEIN; GENE PRODUCT; LEUCINE RICH REPEAT KINASE 2; PARKIN; PROTEIN; PROTEIN PARK5; PROTEIN PARK6; UNCLASSIFIED DRUG; LIGASE; NERVE PROTEIN; SNCA PROTEIN, HUMAN; SYNUCLEIN; THIOL ESTER HYDROLASE; UBIQUITIN PROTEIN LIGASE; UBIQUITIN THIOLESTERASE;

GENE IDENTIFICATION; GENE LOCUS; GENE MAPPING; GENETIC ANALYSIS; GENETIC RISK; GENOME; HUMAN; MUTATION; PARKINSON DISEASE; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; BIOLOGICAL MODEL; BRAIN; GENETICS; LEWY BODY; METABOLISM;

ALPHA-SYNUCLEIN; BRAIN; GENOME, HUMAN; HUMANS; LEWY BODIES; LIGASES; MODELS, GENETIC; NERVE TISSUE PROTEINS; PARKINSON DISEASE; SYNUCLEINS; THIOLESTER HYDROLASES; UBIQUITIN THIOLESTERASE; UBIQUITIN-PROTEIN LIGASES;

EID: 0036591668     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(02)00302-7     Document Type: Review

References (80)

1. New animal models for Parkinson's disease
2. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial
3. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
4. Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. Mov patients with the alpha-synuclein (G209A) mutation
5. Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease
6. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation
7. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease
8. Parkinson's disease is not associated with the combined alpha-synuclein/apolipoprotein E susceptibility genotype
9. Genetic studies in Parkinson's disease with an alpha-synuclein/NACP gene polymorphism in Japan
10. Alpha-Synuclein gene haplotypes are associated with Parkinson's disease
11. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy
12. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations
13. Evidence for a partially folded intermediate in alpha-synuclein fibril formation
14. Conformational properties of alpha-synuclein in its free and lipid-associated states
15. Vesicle permeabilization by protofibrillar alpha-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease
16. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly
17. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure
18. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: A possible factor in Parkinson's disease
19. Alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins
20. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis
21. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein
22. Membrane binding and self-association of alpha-synucleins
23. Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins
24. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease
25. Tetrahydrobiopterin scavenges superoxide in dopaminergic neurons
26. Alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases
27. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease
28. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct
29. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease
30. Beta-Synuclein inhibits alpha-synuclein aggregation: A possible role as an anti-parkinsonian factor
31. Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells
32. Interaction of alpha-synuclein and synphilin-1: Effect of Parkinson's disease-associated mutations
33. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis
34. No evidence of association between a dopamine transporter gene polymorphism (1215A/G) and Parkinson's disease
35. Genetic analysis of synphilin-1 in familial Parkinson's disease
36. Cytosolic O-glycosylation is abundant in nerve terminals
37. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death
38. Human and mouse alpha-synuclein genes: Comparative genomic sequence analysis and identification of a novel gene regulatory element
39. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors
40. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells
41. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis
42. Proteasomal function is impaired in substantia nigra in Parkinson's disease
43. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group
44. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: Expanding the phenotype
45. The parkin gene is not involved in late-onset Parkinson's disease
46. The importance of gene dosage studies: Mutational analysis of the parkin gene in early-onset parkinsonism
47. New mutation (R42P) of the parkin gene in the ubiquitinlike domain associated with parkinsonism
48. The complex relationship between parkin mutations and Parkinson's disease
49. Origin of the mutations in the parkin gene in Europe: Exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects
50. Parkin gene causing benign autosomal recessive juvenile parkinsonism
51. Homozygous deletion mutation of the parkin gene in patients with atypical parkinsonism
52. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations
53. The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations
54. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene
55. Lewy bodies and parkinsonism in families with parkin mutations
56. Novel mutations, pseudo-dominant inheritance, and possible familial affects in patients with autosomal recessive juvenile parkinsonism
57. The parkin gene and its phenotype. Italian PD Genetics Study Group, French PD Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease
58. Pseudo-dominant inheritance and exon 2 triplication in a family with parkin gene mutations
59. Parkin and Parkinson's: More than homonymy?
60. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin
61. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity
62. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1
63. Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain
64. Diverse mutations in the gene for cartilage oligomeric matrix protein in the pseudoachondroplasia-multiple epiphyseal dysplasia disease spectrum
65. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease
66. A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population
67. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms
68. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36
69. Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families
70. PARK6-linked parkinsonism occurs in several European families
71. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36
72. Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset
73. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1
74. Genome-wide scan for Parkinson's disease: The GenePD Study
75. Complete genomic screen in Parkinson disease: Evidence for multiple genes
76. Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene
77. The tau A0 allele in Parkinson's disease
78. Case-Control study of the extended tau gene haplotype in Parkinson's disease
79. Tau and Parkinson disease
80. A susceptibility gene to late-onset idiopathic Parkinson's disease successfully mapped [Abstract 123]